A best evidence topic was written according to a structured protocol. The question addressed was 'In patients requiring an aortic valve replacement, are rapid deployment aortic valve systems better than conventional aortic valve prostheses in terms of mortality, morbidity and/ or valve function?' A total of 508 papers were found using the reported search, of which 11 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The rapid deployment valves (RDVs) implanted in these studies include balloon expandable [Intuity (Edwards Lifesciences, CA, USA) and 3F Enable (Medtronic, MN, USA)] and self-expanding [Perceval (Sorin, Saluggia, Italy)] stented bioprostheses. Available data from these studies demonstrate that rapid deployment valves are invariably associated with shorter aortic cross-clamp times (30-56 vs 49-88 min). Despite this, postoperative mortality (0-5.8 vs 0-6%), ICU (1-3 vs 0.9-2.8 days) and hospital length of stay (6-14.1 vs 6-15.9 days) are similar compared with conventional aortic valve replacement (AVR). However, reduced postoperative bleeding (328 vs 564 ml), blood transfusion requirements (1.4 vs 2.4 units), ventilation time (4.9-9.5 vs 7-16.6 h) and renal injury (5.3 vs 14.7%) have been demonstrated with RDVs indicating possible clinical benefit to shorter procedural time. Importantly, patient risk profiles were similar to or higher across studies in patients undergoing RDVs compared with conventional AVR. From a functional perspective, transvalvular gradients were frequently lower with rapid deployment valves compared with conventional AVR, indicating an improved haemodynamic profile. However, in some studies using the Perceval RDV, the transvalvular gradients were higher than with conventional AVR. Also, mean valve sizes were often larger in those receiving RDVs. Rates of paravalvular regurgitation were similar between RDVs and conventional AVR in most studies, although pacemaker implantation occurred more often with RDV in some studies (2-28.5 vs 0-8.5%). Accepting these limitations, and without long-term data, RDVs would appear to be a reasonable alternative to conventional aortic valve prostheses in selected cases.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You are seeing an 80-year old woman who has chronic obstructive pulmonary disease and Stage III renal impairment, requiring an aortic valve replacement (AVR) for severe calcific aortic stenosis. She has an acceptable functional status, so you would prefer a surgical rather than a transcatheter AVR. However, you are concerned about her pre-existing end-organ dysfunction and general frailty. You have heard about rapid deployment aortic valves as a way to provide a shorter operation and you decide to investigate the outcomes of this option further. Patients also likely to be included in Muneretto et al. [8] Continued Continued reference lists (total 11), that provided the best evidence to answer the question (Table 1) .
RESULTS
Borger et al. Dalen et al. [3] compared Perceval valves (Sorin, Saluggia, Italy) with Edwards Perimount valves. They found no significant differences in 30-day mortality and 2-year survival. However, they found significantly shorter cross-clamp times and lower transfusion rates with the Perceval valve, although with significantly higher permanent pacemaker rates and a trend towards longer intensive care unit (ICU) stays. There was a non-significant trend towards less PVR in the Perceval group (2.3 vs 4.3%).
Vola et al. [4] compared 3F Enable valves (Medtronic, MN, USA) with conventional valves implanted via a mini-sternotomy. They found no significant difference in 30-day mortality or ICU stay. However, they found significantly shorter cross-clamp times, less bleeding and lower mean transvalvular gradients in the 3F Enable group, with a significantly higher rate of pacemaker implantation (7.3 vs 0%) and a trend towards a greater PVR in the 3F Enable group (2 vs 0%). Mean implanted valve size was larger in the RDV group (23.4 ± 2.1 vs 22.4 ± 13.7 mm).
Gilmanov et al. [5] compared outcomes following implantation of predominantly the Perceval valve with those following conventional bioprosthetic or mechanical AVR. They found no significant difference in hospital mortality, overall survival or rates of complete heart block. However, aortic cross-clamp (56 vs 88 min) and ventilation (6 vs 7 h) times were significantly shorter for the RDVs.
A study by Konig et al. [6] comparing the Perceval RDV with Edwards Perimount bioprostheses found no deaths in either group at 30 days but a significantly shorter isolated AVR crossclamp time (37.3 ± 6.8 vs 49.1 ± 11.2 min) in the Perceval group. There was a trend towards more pacemaker implantations (28.5 vs 7.1%) and significantly higher peak transvalvular gradients in the Perceval group (24.8 ± 5.2 vs 19.0 ± 6.5 mmHg).
Two studies by Muneretto et al. [7, 8] and the one by D'Onofrio et al. [9] compared the Perceval RDV with both conventional AVR and TAVI. All three studies reported equivalent mortality rates following RDV implantation and conventional AVR. Muneretto's earlier study [7] demonstrated similar pacemaker implantation rates between RDV and conventional AVR, whereas their later study [8] showed a greater pacemaker implantation rate, shorter ICU stay, ventilation duration and less kidney injury with RDV compared with conventional AVR. All three studies demonstrated lower transvalvular gradients following RDV implantation compared with conventional AVR. Both studies by Muneretto et al. showed no significant difference between conventional AVR and Perceval RDV in rates of PVR, but D'Onofrio et al. showed a sizeable difference (19.4 vs 1.8%).
Pollari et al. [10] and Shrestha et al. [11] compared the Perceval RDV with stented bioprostheses, whereas Santarpino et al. [12] included stentless bioprostheses and mechanical valves. All three studies found no significant difference in 30-day mortality but significantly shorter cross-clamp times for the Perceval group. Pollari et al. [10] and Santarpino et al. [12] 
CLINICAL BOTTOM LINE
Rapid deployment valves are associated with shorter aortic crossclamp times, although postoperative mortality, ICU and hospital stay, and short-term survival are similar to conventional AVR. However, the use of RDVs is associated with reduced bleeding, blood transfusion requirements, ventilation time and renal injury. Overall, RDVs appear to have favourable valve haemodynamics compared with conventional aortic bioprostheses, although in some studies, the reverse is true. Mean valve sizes were often higher in those receiving RDVs. Rates of PVR and PPM implantation are similar to or higher with RDVs. Accepting these limitations, and without long-term data, RDVs would appear to be a reasonable alternative to conventional aortic valve prostheses in selected cases.
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